8-K: Tonix Pharmaceuticals to Present Tonmya Data at ASCP Annual Meeting, NDA Submission Planned

Tonix Pharmaceuticals will present data on Tonmya (TNX-102 SL) for fibromyalgia and other programs at the American Society of Clinical Psychopharmacology Annual Meeting, with a New Drug Application (NDA) submission planned for the second half of 2024.

Summary

• Tonix Pharmaceuticals announced it will present an oral presentation and two posters at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting from May 28-31, 2024.
• The oral presentation will focus on the Phase 3 RESILIENT trial results of Tonmya (TNX-102 SL) in fibromyalgia, highlighting its effects on mood and anxiety symptoms.
• One poster will detail a Phase 2 proof-of-concept study of TNX-102 SL in fibromyalgia-type Long COVID.
• The second poster will describe an upcoming investigator-initiated Phase 2 trial of TNX-102 SL for acute stress disorder and prevention of posttraumatic stress disorder after motor vehicle collisions, sponsored by the University of North Carolina.
• Tonix plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya for the management of fibromyalgia.
• A Type B pre-NDA meeting with the FDA is scheduled for the second quarter of 2024.

Sentiment

Score: 8

Explanation: The document is positive due to the successful Phase 3 trial results and the planned NDA submission. The expansion into new therapeutic areas also adds to the positive outlook. However, the inherent risks in drug development temper the sentiment slightly.

Positives

• The Phase 3 RESILIENT trial of Tonmya met its primary endpoint, showing a significant reduction in daily pain compared to placebo.
• The RESILIENT trial also demonstrated significant improvements in key secondary endpoints, including sleep quality, fatigue, and overall fibromyalgia symptoms.
• Tonix is advancing its NDA submission for Tonmya, indicating progress towards potential market approval.
• The company is exploring additional applications of TNX-102 SL in Long COVID and acute stress disorder, expanding its potential market reach.
• The upcoming investigator-initiated Phase 2 trial for acute stress disorder highlights the potential for TNX-102 SL in a new therapeutic area.

Negatives

• The document does not explicitly mention any negative aspects of the results or the company's performance.
• The document does not mention any specific risks or challenges related to the NDA submission process.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including the failure to obtain FDA clearances or approvals.
• There are risks related to the failure to successfully market any of the company's products.
• The timing and progress of clinical development of product candidates are subject to risks.
• The company may need additional financing.
• There are uncertainties of patent protection and litigation.
• There are uncertainties of government or third-party payor reimbursement.
• The company faces substantial competition.
• There are significant risks in the development, regulatory approval, and commercialization of new products.

Future Outlook

Tonix plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya for the management of fibromyalgia.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer, will present the oral presentation on the effects of TNX-102 SL on mood and anxiety symptoms in fibromyalgia.
• Herbert Harris, M.D., Ph.D., Executive Vice President, Translational Medicine, will present a poster on the effects of TNX-102 SL in fibromyalgia-type Long COVID.
• David Hsu, Ph.D., Senior Scientist, will present a poster on optimizing acute stress reaction interventions with TNX-102 SL.

Industry Context

This announcement is relevant to the pharmaceutical industry, particularly in the areas of central nervous system disorders and pain management. The presentation of clinical trial data at a major conference like ASCP is a key step in the drug development and commercialization process. The focus on fibromyalgia and Long COVID also aligns with current unmet medical needs.

Comparison to Industry Standards

• The Phase 3 RESILIENT trial results for Tonmya, showing a statistically significant reduction in pain and improvements in sleep and fatigue, are comparable to or better than results seen in other fibromyalgia treatments.
• The planned NDA submission in the second half of 2024 is a standard timeline for a drug that has completed Phase 3 trials.
• The exploration of TNX-102 SL in Long COVID and acute stress disorder is innovative and could position Tonix as a leader in these emerging therapeutic areas.
• Companies like Eli Lilly (Cymbalta) and Pfizer (Lyrica) have established treatments for fibromyalgia, and Tonix will need to demonstrate a competitive advantage to gain market share.

Stakeholder Impact

• Shareholders may react positively to the successful trial results and the planned NDA submission.
• Patients with fibromyalgia may benefit from a new treatment option.
• Healthcare providers will have access to new data on Tonmya.
• Employees of Tonix may be positively impacted by the company's progress.

Next Steps

• Tonix will deliver an oral presentation and present two posters at the ASCP Annual Meeting from May 28-31, 2024.
• Tonix will hold a Type B pre-NDA meeting with the FDA in the second quarter of 2024.
• Tonix plans to submit an NDA to the FDA in the second half of 2024 for Tonmya for the management of fibromyalgia.

Key Dates

Keywords

Tonix Pharmaceuticals, Tonmya, TNX-102 SL, Fibromyalgia, Long COVID, Acute Stress Disorder, NDA, ASCP, Clinical Trials, RESILIENT Trial